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What needs to be done?
Regardless of the structural environment of any given country,
public health officials in all European countries need to argue for
the importance of monitoring the health of sexual and gender
minority individuals and promote the inclusion of brief survey
questions and practicable assessment structures regarding sexual
and gender minority experiences to national and European-wide
agencies with responsibilities for population health monitoring.
The inclusion of a few straightforward questions in population
health monitoring surveys, with strong guarantees that sensitive
personal information will be protected by universal safeguards, is a
feasible goal which would vastly increase the public health field’s
ability to study and reduce the disproportionate ill health affecting
sexual and gender minority individuals across Europe.4,5
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T
obacco is distinct in the harm to health it causes, and is produced
by an industry which requires a special form of regulation. Such
recognition has been crucial to advances in tobacco control and is
known as tobacco exceptionalism.1 Paradoxically, this idea may now
limit progress in global health by obscuring how hard won lessons
may apply to other commercial sectors that damage people’s health.1
Tobacco is produced by a highly concentrated and globalized
industry, whose behavior over many decades has been shown to
have transgressed the most basic ethical responsibilities towards
human life in pursuit of profit. The tobacco companies are now
accepted as requiring a distinct model of governance, which
includes the protection of public health policies from interference
because of ‘a fundamental and irreconcilable conflict between the
tobacco industry’s interests and public health policy’.2 This position
is enshrined in a binding United Nations treaty in the World Health
Organization Framework Convention on Tobacco Control (WHO
FCTC). Tobacco companies’ internal documents constitute an
unusually strong form of evidence on their internal machinations.
These show that the tobacco companies continue to understand very
well that their business interests are compromised by public health
policies, and for this reason continue to oppose them strongly.
Alcohol has been used for millennia as an intoxicating drug.
Alcohol is different from tobacco in many respects. We do not
expect that alcohol will kill half its users, and a minority of
drinkers are addicted to alcohol. Instead, the public health burden
arises predominantly from the larger number who drink in risky
rather than in obviously problematic ways. Alcohol kills fewer
people than tobacco globally, approximately 5% compared to 8%
of all deaths, though it may be more likely to be under-reported.
Alcohol is a component cause of more than 200 diseases, injuries
and other health problems, of which more than 40 are wholly at-
tributable. Alcohol is carcinogenic and toxic and kills at younger
ages and in some different ways to tobacco, including through
violence associated with intoxication.
Alcohol is responsible for social problems, including the need to
fund healthcare services. In England the costs to the NHS and wider
society are approximately £2.5 and £11 billion respectively for
tobacco, compared to £3.5 and £21 billion for alcohol. Both
alcohol and tobacco do more damage in socioeconomically
deprived populations and exacerbate health inequalities. Public
health policies threaten the business interests of alcohol
companies, similarly to tobacco companies.
Alcohol is more profitable than other consumer goods apart from
tobacco, and profitability in the largest companies approaches that
found in tobacco companies. Both industries derive their profitabil-
ity from unhealthy levels of consumption, and the alcohol industry,
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particularly in beer and spirits, increasingly resembles the tobacco
industry as fewer companies dominate global production.
The tobacco company internal documents reveal how the two
industries have long collaborated in advancing shared interests in
influencing policy, and importantly, they show that there is a long
history of cross ownership that makes it unwise to think of them as
separate entities.3 More recently, tobacco company parent company
Altria strongly supported the third largest merger in corporate
history to create the world’s largest alcohol producer, and
purchased additional shares to become the second largest share-
holder upon completion.4
Pricing and availability restrictions are the key policy measures
that evidence indicates are most likely to be effective for alcohol,
similar to tobacco. Whilst restrictions are widely implemented as
public health measures for tobacco, they are much less prominent
in national alcohol policies. National alcohol policies frequently
emphasize partnerships with industry that would be unthinkable
for tobacco companies, yet permit alcohol industry actors wide-
ranging influence.
A minority of the world’s population uses either drug, so there are
markets to be developed, especially in Low- and Middle-Income
Countries. The most recent report on alcohol from WHO reveals
no progress in reducing total global per capita alcohol consumption,
which is instead forecast to rise.5 This will have predictable conse-
quences for death, disease and social problems. It is highly likely that
the key Sustainable Development Goals’ target for the harmful use of
alcohol will not be met, unless effective policies to protect public
health are more widely adopted and implemented.
The achievements of tobacco control rest in part on tobacco ex-
ceptionalism. This comparison with alcohol suggests that tobacco
may not actually be so different in the challenges posed and the
responses required. There have been encouraging signs of integrative
perspectives on the global health implications of commercial actors’
business activities and how we address them. The potential value of
policy coherence, not only in respect of global health more broadly,
but for tobacco control itself has also previously been recognized.1
The progress already made in tobacco control means that important
lessons are available to protect and improve health more widely.
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